National Survey on Gastroesophageal Reflux Disease (GERD) Patients
Completed
- Conditions
- GERD
- Registration Number
- NCT00695838
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this observational study is to assess the impact of abdominal fat on severity and frequency of GERD symptoms .
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5084
Inclusion Criteria
- Male or female > or = 18 years old
- Patient with symptomatic GERD
- Without PPI or H2 antagonist treatment during the 3 previous months
- Agree to take part in this study
Exclusion Criteria
- Pregnant women
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Waist circumference Once
- Secondary Outcome Measures
Name Time Method Frequency of GERD symptoms Once GERD impact scale Once
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link abdominal fat to GERD symptom severity and frequency in NCT00695838?
How does the impact of abdominal fat on GERD in NCT00695838 compare to proton pump inhibitors in general practice?
Are there specific biomarkers associated with abdominal fat that predict GERD severity in observational studies?
What adverse events are commonly reported in GERD patients with high abdominal fat in AstraZeneca's research?
What related compounds or combination therapies are being explored for GERD alongside lifestyle interventions?
Trial Locations
- Locations (1)
Research Site
🇫🇷Yvre L Eveque, France
Research Site🇫🇷Yvre L Eveque, France